X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Dishman Pharma with Aurobindo Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DISHMAN PHARMA vs AUROBINDO PHARMA - Comparison Results

DISHMAN PHARMA    Change

Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More

AUROBINDO PHARMA 
   Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DISHMAN PHARMA AUROBINDO PHARMA DISHMAN PHARMA/
AUROBINDO PHARMA
 
P/E (TTM) x 25.1 17.7 141.4% View Chart
P/BV x 3.3 5.8 58.0% View Chart
Dividend Yield % 0.7 0.4 184.8%  

Financials

 DISHMAN PHARMA   AUROBINDO PHARMA
EQUITY SHARE DATA
    DISHMAN PHARMA
Mar-16
AUROBINDO PHARMA
Mar-16
DISHMAN PHARMA/
AUROBINDO PHARMA
5-Yr Chart
Click to enlarge
High Rs3741,541 24.3%   
Low Rs129582 22.1%   
Sales per share (Unadj.) Rs197.8237.5 83.3%  
Earnings per share (Unadj.) Rs21.233.9 62.6%  
Cash flow per share (Unadj.) Rs34.740.6 85.6%  
Dividends per share (Unadj.) Rs2.002.50 80.0%  
Dividend yield (eoy) %0.80.2 337.4%  
Book value per share (Unadj.) Rs179.9120.6 149.2%  
Shares outstanding (eoy) m80.69585.17 13.8%   
Bonus/Rights/Conversions -PREF-  
Price / Sales ratio x1.34.5 28.5%   
Avg P/E ratio x11.931.3 37.9%  
P/CF ratio (eoy) x7.226.2 27.7%  
Price / Book Value ratio x1.48.8 15.9%  
Dividend payout %9.47.4 127.8%   
Avg Mkt Cap Rs m20,306621,041 3.3%   
No. of employees `0000.813.3 6.2%   
Total wages/salary Rs m5,35515,508 34.5%   
Avg. sales/employee Rs Th19,252.710,457.6 184.1%   
Avg. wages/employee Rs Th6,459.51,167.1 553.5%   
Avg. net profit/employee Rs Th2,064.11,491.6 138.4%   
INCOME DATA
Net Sales Rs m15,961138,961 11.5%  
Other income Rs m2651,663 16.0%   
Total revenues Rs m16,226140,624 11.5%   
Gross profit Rs m4,10332,056 12.8%  
Depreciation Rs m1,0913,926 27.8%   
Interest Rs m9442,568 36.8%   
Profit before tax Rs m2,33427,225 8.6%   
Minority Interest Rs m039 0.0%   
Prior Period Items Rs m10-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m6247,444 8.4%   
Profit after tax Rs m1,71119,820 8.6%  
Gross profit margin %25.723.1 111.4%  
Effective tax rate %26.727.3 97.7%   
Net profit margin %10.714.3 75.2%  
BALANCE SHEET DATA
Current assets Rs m11,018100,015 11.0%   
Current liabilities Rs m9,51774,759 12.7%   
Net working cap to sales %9.418.2 51.7%  
Current ratio x1.21.3 86.5%  
Inventory Days Days110107 102.9%  
Debtors Days Days35110 31.8%  
Net fixed assets Rs m16,30452,350 31.1%   
Share capital Rs m161585 27.6%   
"Free" reserves Rs m12,90767,707 19.1%   
Net worth Rs m14,51670,567 20.6%   
Long term debt Rs m4,1898,472 49.4%   
Total assets Rs m29,805156,994 19.0%  
Interest coverage x3.511.6 29.9%   
Debt to equity ratio x0.30.1 240.4%  
Sales to assets ratio x0.50.9 60.5%   
Return on assets %8.914.3 62.5%  
Return on equity %11.828.1 42.0%  
Return on capital %17.537.7 46.4%  
Exports to sales %24.851.0 48.6%   
Imports to sales %3.718.8 19.8%   
Exports (fob) Rs m3,95670,927 5.6%   
Imports (cif) Rs m59626,193 2.3%   
Fx inflow Rs m4,95271,015 7.0%   
Fx outflow Rs m69728,799 2.4%   
Net fx Rs m4,25542,216 10.1%   
CASH FLOW
From Operations Rs m2,78617,596 15.8%  
From Investments Rs m-1,529-13,801 11.1%  
From Financial Activity Rs m-941-198 474.6%  
Net Cashflow Rs m3163,597 8.8%  

Share Holding

Indian Promoters % 61.4 54.1 113.5%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 3.7 8.0 46.5%  
FIIs % 12.7 27.7 45.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 22.1 10.2 216.7%  
Shareholders   46,261 69,601 66.5%  
Pledged promoter(s) holding % 35.8 8.6 417.8%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DISHMAN PHARMA With:   MERCK LTD  STERLING BIOTECH  ASTRAZENECA PHARMA  VENUS REMEDIES  IPCA LABS  

Compare DISHMAN PHARMA With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Post Noon Sell-Off; Infosys Falls 5.4%(Closing)

Share markets in India witnessed a sharp fall in the final minutes of trade. At the closing bell, the BSE Sensex closed lower by 266 points. While, the NSE Nifty finished lower by 83 points.

Related Views on News

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

The Power of 5 Minutes (The 5 Minute Wrapup)

Jun 16, 2017

Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

More Views on News

Most Popular

A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

Aug 10, 2017

Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

The Most Profitable Investment in the History of the World(Vivek Kaul's Diary)

Aug 8, 2017

'Yes, it looks like a bubble. And, yes, it's like buying a lottery ticket. But there's something happening that has never happened before. It's an evolutionary leap in money itself.'

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

Bitcoin Continues Stellar Rise(Chart Of The Day)

Aug 10, 2017

Bitcoin hits an all-time high, is there more upside left?

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DISHMAN PHARMA SHARE PRICE


May 29, 2017 (Close)

TRACK DISHMAN PHARMA

  • Track your investment in DISHMAN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DISHMAN PHARMA

DISHMAN PHARMA 8-QTR ANALYSIS

COMPARE DISHMAN PHARMA WITH

MARKET STATS